Nanosonics boss Michael Kavanagh says the company can meet market expectations for 20 per cent plus sales growth this year, underpinned by a recovery in ultrasound appointments in the United States and at home as vaccination rates climb.

The company’s shares surged 21.9 per cent to $7.18 on Tuesday, pushing its market value up by over $380 million to $2.16 billion after it staged a major recovery in the second half of fiscal 2021.